Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K8 | P41279 | 6/20 | 0.86 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 4/20 | 0.46 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.46 |
| ▸ | GSK3A | P49840 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.46 |
| ▸ | PLK4 | O00444 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5555891 | 0.84 | MAP3K8 (0.76) | MAP3K8MAP2K1MAPK1JAK3PIM1 | |
| SCHEMBL5550771 | 0.82 | MAP3K8 (0.81) | MAP3K8MAP2K1MAPK1JAK3JAK2 | |
| SCHEMBL5550318 | 0.75 | MAP3K8 (0.53) | MAP3K8MAP2K1MAPK1JAK3JAK2 | |
| SCHEMBL5549992 | 0.73 | MAP3K8 (0.58) | MAP3K8MAP2K1MAPK1PIM1MAPK9 | |
| SCHEMBL5554165 | 0.73 | MAP3K8 (0.60) | MAP3K8MAP2K1MAPK1PIM1MAPK9 | |
| SCHEMBL5555935 | 0.73 | MAP3K8 (1.00) | MAP3K8MAP2K1MAPK1JAK3PIM1 | |
| SCHEMBL18889226 | 0.72 | MAP3K8 (0.71) | MAP3K8PIM1MAPK9GSK3AGSK3B | |
| SCHEMBL27738181 | 0.68 | RAB9A (0.58) | MAP3K8MAP2K1MAPK1ALDH1A1NPC1 | |
| SCHEMBL5555951 | 0.68 | MAP3K8 (0.51) | MAP3K8MAP2K1MAPK1PIM1MAPK9 | |
| SCHEMBL5550688 | 0.68 | BRAF (0.49) | MAP3K8MAP2K1MAPK1AURKBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753428-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | MAP3K8 13/4885MAP2K1 216/4885MAPK1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.